NBIX

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 10

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 9

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,721

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 16

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,665

Underlying: Common Stock · 11,775 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years.

SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 15

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,005

Underlying: Common Stock · 14,140 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Option granted January 31, 2022 and vested monthly over four years.

SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 14

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,742 shares

Expires 2028-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019.

SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 13

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,742

Underlying: Common Stock · 38,722 shares

Expires 2028-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 8

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 7

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,296

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 6

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 5

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 4

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 3

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,243

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-057986 · doc4.xml · derivative · entry 3

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,464

Underlying: Common Stock · 8,396 shares

Expires 2028-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019.

SEC source: 0001209191-23-057986 · doc4.xml · nonDerivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 28,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

SEC source: 0001209191-23-057986 · doc4.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,917

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,376

Underlying: Common Stock · 20,830 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years.

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,882

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.81 to $120.0350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-23-000082 · wk-form4_1702077782.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · derivative · entry 3

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2024-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year.

SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · nonDerivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,697

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0000914475-23-000080 · wk-form4_1701813271.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-057097 · doc4.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,732

F1 · kind: Sale of 2,331 shares of common stock issued upon vesting of 4,425 restricted stock units on November 29, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,094) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.17 to $113.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-056907 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,882

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.21 to $113.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-056033 · doc4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,305

F1 · shares: This transaction represents a gift/charitable contribution effective November 16, 2023. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

SEC source: 0001209191-23-052028 · doc4.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,894

F1 · kind: Sale of 1,437 shares of common stock issued upon vesting of 2,732 restricted stock units on October 2, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,295) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes an aggregate of 139 shares purchased on August 31, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-23-049448 · doc4.xml · derivative · entry 3

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2024-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year.

SEC source: 0001209191-23-049448 · doc4.xml · nonDerivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,697

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0001209191-23-049448 · doc4.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-048383 · doc4.xml · derivative · entry 3

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires 2024-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year.

SEC source: 0001209191-23-048383 · doc4.xml · nonDerivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,697

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0001209191-23-048383 · doc4.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-048381 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001209191-23-047968 · doc4.xml · nonDerivative · entry 2

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,460

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.23 to $108.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047968 · doc4.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,898

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001209191-23-047966 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,801

SEC source: 0001209191-23-047747 · doc4.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,931

F1 · kind: Sale of 1,431 shares of common stock issued upon vesting of 2,717 restricted stock units on August 28, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,286) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F1 · shares: Sale of 1,431 shares of common stock issued upon vesting of 2,717 restricted stock units on August 28, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,286) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0001209191-23-047140 · doc4.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,521

F1 · kind: Sale of 3,198 shares of common stock issued upon vesting of 6,075 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,877) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: 25,459 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

SEC source: 0001209191-23-047139 · doc4.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,638

F1 · kind: Sale of 3,198 shares of common stock issued upon vesting of 6,075 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,877) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: Includes an aggregate of 236 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-23-047138 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,991

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047137 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,754

F1 · kind: Sale of 9,328 shares of common stock issued upon vesting of 17,717 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (8,389) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

SEC source: 0001209191-23-047135 · doc4.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,250

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: Includes an aggregate of 236 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-23-047134 · doc4.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,645

F1 · kind: Sale of 1,404 shares of common stock issued upon vesting of 2,667 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,263) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047133 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,087

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047132 · doc4.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,193

F1 · kind: Sale of 1,600 shares of common stock issued upon vesting of 3,038 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,438) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047128 · doc4.xml · nonDerivative · entry 1

BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,436

F1 · kind: Sale of 1,600 shares of common stock issued upon vesting of 3,038 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,438) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-047127 · doc4.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,131

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-23-042239 · doc4.xml · derivative · entry 1

POON CHRISTINE A · CIK 0001189014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,375

Underlying: Common Stock · 16,375 shares

Expires 2033-07-11

F1 · derivative.exercise_date: Option vests in 36 monthly installments beginning August 11, 2023.

SEC source: 0001209191-23-031131 · doc4.xml · derivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,199

Underlying: Common Stock · 4,199 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024.

F2 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024.